Drugs / EC1169
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02202447 | May 2014 → Nov 2018 | prostate cancer | Endocyte | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EC1169 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02202447 ↗ |
| Route | Intravenous | “EC1169 - Dose dependent on cohort, IV (in the vein) on days 1 and 8 of each 21 day cycle” NCT02202447 ↗ |